Form 4: Dianthus Therapeutics Chief Medical Officer Simrat Randhawa Reports Stock Option Grant
SEC Form 4 Filing
Simrat Randhawa, Chief Medical Officer of Dianthus Therapeutics, reports the acquisition of stock options exercisable for 150,000 shares of common stock.
Summary
- On February 3, 2025, Simrat Randhawa, the Chief Medical Officer of Dianthus Therapeutics, Inc., was granted stock options to purchase 150,000 shares of the company's common stock.
- The exercise price of the options is $22.07 per share.
- The options vest in equal monthly installments over four years, starting January 1, 2025, contingent upon Randhawa's continued service to Dianthus Therapeutics.
- The expiration date for these options is February 2, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The grant of stock options to the Chief Medical Officer aligns their interests with those of the shareholders, incentivizing them to contribute to the company's long-term success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- The size of the grant is likely determined by factors such as the executive's role, experience, and the company's overall compensation strategy.
- Comparable companies such as argenx SE and Immunovant Sciences also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's success.
- Employees may see this as a positive sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Vesting of stock options begins. |
| February 3, 2025 | Date of stock option grant. |
| February 2, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.